6 May 2025 in Journal of the American Heart Association
Background: A good prognosis of congenital heart disease (CHD) depends on early diagnosis and intervention. Under the current screening conditions, a significant proportion still go undetected. Metabolomics, as a phenotype‐correlated research methodology, remains underused in the study of CHD, which could provide the possibility to screen neonatal CHD efficiently. Methods: Data for the analysis are from >22 000 neonates captured in the Network Platform for CHD from April 2020 to November 2021 in 11 cities in China. After data matching and quality control, a total of 22 674 neonates were finally included and divided into the CHD group (n=1823), nonsignificant CHD group (n=17 968), and normal group (n=2748). Demographic and clinical characteristics and tandem mass spectrometry‐based metabolic data for genetic and metabolic disease screening were gathered and compared for all groups. Machine learning models based on metabolic biomarkers were constructed to screen CHD in neonates. Results: After quality control, 22 539 neonates were ultimately included. Among them, 1823 were diagnosed with CHD, 17 968 were nonsignificant CHD, and 2748 were normal. A total of 46 distinguishing metabolic biomarkers were identified, and we found that the CHD group had significantly lower levels of 17‐hydroxyprogesterone (CHD versus nonsignificant CHD, P <0.001, log 2 fold change=−0.16; CHD versus normal, P <0.001, log 2 fold change=−0.15). We constructed CHD and ventricular septal disease screening models based on metabolic biomarkers. The best fitting model achieved an area under the receiver operating characteristic curve of 0.745 (95% CI, 0.696–0.791). Conclusions: This study reveals the unique metabolic profile of neonates with CHD. The screening model demonstrates considerable potential in early neonatal CHD screening and reflects significant value from a health economics perspective.
30 September 2025 in World Journal of Pediatric Surgery
Pulmonary atresia with an intact ventricular septum (PA/IVS) is a rare congenital heart disease. Pulmonary regurgitation is a major late postsurgical complication and pulmonary valve replacement is the mainstream treatment. We report the case of a 15-year-old boy with PA/IVS who developed severe pulmonary regurgitation after prior surgical repair. Intraoperative angiography revealed the absence of bilateral femoral venous trunks, making transcatheter pulmonary valve replacement (TPVR) not feasible. Transthoracic pulmonary valve replacement using a self-expanding Venus P-Valve was successfully performed. Postoperative recovery was uneventful, and follow-up showed good valve function and improved right ventricular performance. Transthoracic implantation of a self-expanding pulmonary valve may serve as a safe and feasible alternative for patients with severe pulmonary regurgitation who are unsuitable for TPVR due to unfavorable vascular anatomy.